1. The Task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). ESC/EAS guidelines for the management of dyslipidaemias;Eur Heart J,2011
2. Executive summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection;Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults;JAMA,2001
3. U.S. Food and Drug Administration (FDA). Health claims: soluble fiber from certain foods and the risk of coronary heart disease (CHD). Code of Federal Regulations Title 2; Section 101.81 [Internet]. Silver Spring (MD): FDA. 1997 [updated 2014 Sep 1; cited 2013 Nov 14]. Available from: www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRSearch.cfm?fr=101.81.
4. Bureau of Nutritional Sciences, Food Directorate, Health Products and Food Branch, Health Canada. Oat products and blood cholesterol lowering: summary of assessment of a health claim about oat products and blood cholesterol lowering [Internet]. Ottawa, Ontario: Health Canada. 2010 [cited 2013 Nov 14]. Available from: www.hc-sc.gc.ca/fn-an/label-etiquet/claims-reclam/assess-evalu/oat-avoine-eng.php.
5. Scientific opinion on the substantiation of a health claim related to oat beta-glucan and lowering blood cholesterol and reduced risk of (coronary) heart disease pursuant to Article 14 of Regulation (EC) No 1924/2006;EFSA Panel on Dietetic Products;EFSA J,2010